From Company update -
In June, the Company was made aware of a UK lawsuit filed by Exelogen, Inc. against the University
of Birmingham in relation to certain intellectual property rights to Exenatide. Invex Therapeutics
is not a party to this lawsuit, with all intellectual property rights to Exenatide patent applications
assigned to Invex by the University of Birmingham on 12 March 2019.
Pretty much all I need to hear.
University of Birmingham Lawsuit, page-54
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.885M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49728 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 7950 | 1 |
View Market Depth
| Last trade - 13.27pm 03/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable